Navigation Links
Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
Date:6/8/2009

SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- Dr. Steven Josephs, Ph.D., a former National Cancer Institute (NCI) researcher, has joined Entest BioMedical Inc.'s (www.entestbio.com) Science Advisory Board where he will focus on expanding the company's stem cell cancer research. Dr. Josephs' NCI research involved studies of the human T-cell leukemia virus, HIV and Human Herpervirus-6 genetic characterization. Josephs also worked for Baxter Healthcare and GenStar Therapeutics where he focused on the cellular and molecular biology of gene therapy for hemophilia. Entest BioMedical Inc. is a wholly-owned subsidiary of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN; www.BMSN.us).

According to David Koos, Chairman and CEO of both Entest BioMedical Inc. and Bio-Matrix Scientific Group Inc., "Dr. Josephs' extensive cancer research background adds strength to our growing Scientific Advisory Board. His insight into potential stem cell therapies for cancer patients will help expedite Entest BioMedical's goal of providing innovative stem cell transplantation therapies and services including autologous and allogenic peripheral blood or bone marrow transplantation.

Dr. Feng Lin, Director of Research for Entest BioMedical and Bio-Matrix Scientific Group, also applauded the addition of Dr. Josephs' to the Science Advisory Board. "Dr. Josephs joins our life science team at exactly the right time," said Lin. "We're currently interested in differentiating hematopoietic stem cells into immune cells especially T-cells. Dr. Josephs will work with us on our research goal of generating a new population of immune cells from a patient's own stem cells to reactivate the patient's immune system. This strategy represents a novel and effective immunotherapy especially for cancer patients and HIV patients who have injured immune systems and are at high risk of infection with bacteria and viruses."

About Entest BioMedical Inc.:

Entest BioMedical, Inc., a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTC BB: BMSN) formed in April 2009, focuses on research and development of traumatic brain injury (TBI) and spinal cord injury using autologous 'adipose-derived' stem cells. Entest BioMedical is involved with R&D activities relating to stem cell therapies, diabetes testing and medical devices.

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
2. New Video Series Spotlights Role of Biomedical Engineers in Caring for Total Artificial Heart Patients
3. Response Biomedical Closes $12.65 million Unit Offering
4. Garth Fisher, M.D., F.A.C.S., World Renowned Plastic Surgeon and Co-Founder Of CellCeuticals(R) Biomedical Skin Treatments Revealed On E!s Keeping Up With The Kardashians as the Surgeon Behind Bruce Jenners New Face
5. Response Biomedical Announces Proposed Unit Offering
6. Dr. Abbott J. Krieger Joins Avery Biomedical Devices, Inc. as Chief Clinical Liaison
7. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
8. BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivans Product Innovation of the Year Award
9. Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards
10. Response Biomedical Corporation Reports 2008 Financial Results
11. Advance Internet Launches HireBioMedical.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... Wharton Seminars for Business Journalists , led by the Wharton School’s most ... economic issues.  This one-day program at the Wharton School’s San Francisco campus ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), the ... the latest addition to its family of Partner Firms. Headquartered in Mount Pleasant, ... human resources, and health care consumerism specialists. , “Partnering with UBA will enable ...
(Date:5/5/2016)... Ridgeland, MS (PRWEB) , ... May 05, 2016 ... ... life-threatening medical conditions and Make-A-Wish grants the most heartfelt wishes of these children. ... long rounds of medical treatment. President and CEO of Make-A-Wish Mississippi, Brent ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the Midwest Business ... employees to understand and use the free preventive care benefits available to them as ... groups of large, self-insured public and private employers, MBGH found that only 10% of ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... First quarter 2016 adjusted diluted earnings per share (EPS) ... First quarter reported diluted (GAAP) loss per share from ... 2016 financial guidance; now expects 2016 revenues to range from ... earnings per share to range from $4.50 to $4.80 ... manufacturing facility restructuring , Company expands Board ...
(Date:5/5/2016)... COUNTY, Calif. , May 5, 2016 /PRNewswire/ ... nearly a decade due to concerns that these ... in the approach to imaging, as well as ... a new era of medical peripherals that help health ... care.   Ampronix  advanced medical imaging is a renowned ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology: